Premium
Evaluation of magnetic resonance imaging‐based prostate‐specific antigen density of the prostate in the diagnosis of prostate cancer
Author(s) -
Hoshii Tatsuhiko,
Nishiyama Tsutomu,
Toyabe Shinichi,
Akazawa Kohei,
Komatsu Shuichi,
Kaneko Masaaki,
Hara Noboru,
Takahashi Kota
Publication year - 2007
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2007.01686.x
Subject(s) - medicine , magnetic resonance imaging , prostate cancer , transrectal ultrasonography , prostate , prostate specific antigen , urology , receiver operating characteristic , nuclear medicine , radiology , cancer
Objectives: We evaluated prostate‐specific antigen (PSA) density of the prostatic volume (PSAD) estimated using transrectal ultrasonography (TRUS; TRUS‐based PSAD), magnetic resonance imaging (MRI; MRI‐based PSAD), and PSA density of the transition zone (TZ) volume (PSATZD) estimated using MRI (MRI‐based PSATZD) in the diagnosis of prostate cancer (PCa). Methods: One hundred and twenty patients, who were suspected to have PCa based on PSA, ranged between 4.1 and 20.0 ng/mL were enrolled in this study. Results: The prostatic volume estimated using TRUS was smaller than the volume estimated using MRI by 11.4% in the patients with PSA levels ranging 4.1–20.0 ng/mL, 7.2% in those 4.1–10.0 ng/mL, and 15.7% in those 10.1–20.0 ng/mL, respectively. PSA levels were correlated with the prostatic volume estimated using TRUS and MRI, and TZ volume estimated using MRI in the patients without PCa; however, the level was not correlated with them in the patients with PCa. The area under the receiver operating characteristic curve of MRI‐based PSAD was higher than that of TRUS‐based PSAD; however, there was no statistical difference. Stepwise logistic regression analysis for the prediction of PCa by using PSA‐related parameters confirmed that MRI‐based PSATZD was the most significant predictor in patients with PSA levels in the range of 4.1–20.0 ng/mL ( P < 0.001), the range of 4.1–10.0 ng/mL ( P = 0.002), and the range of 10.1–20.0 ng/mL ( P < 0.001), respectively. Conclusions: The prostatic volume estimated using TRUS was smaller than the volume estimated using MRI. MRI‐based PSATZD is the most significant predictor in the four parameters.